BioLine RX LtdNASDAQ:BLRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6328
- TODAY'S CHANGE (%)-0.0072 (-1.1250%)
- Bid / Lots0.6320/ 1
- Ask / Lots0.6400/ 16
- Open / Previous Close0.6589 / 0.6400
- Day Range
- 52 Week Range
- Volume44,906
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BLRX |
|---|---|---|
| 09:32 ET | 3028 | 0.65 |
| 09:34 ET | 4000 | 0.664899 |
| 09:36 ET | 1000 | 0.65 |
| 09:38 ET | 1000 | 0.651 |
| 09:56 ET | 900 | 0.6469 |
| 09:57 ET | 990 | 0.64 |
| 10:01 ET | 700 | 0.6425 |
| 10:08 ET | 100 | 0.640602 |
| 10:14 ET | 100 | 0.645 |
| 10:21 ET | 972 | 0.6406 |
| 10:51 ET | 2686 | 0.645 |
| 10:55 ET | 100 | 0.645 |
| 11:51 ET | 3700 | 0.6407 |
| 11:58 ET | 100 | 0.645 |
| 12:03 ET | 1300 | 0.6408 |
| 12:30 ET | 1500 | 0.6407 |
| 12:36 ET | 1000 | 0.645 |
| 12:43 ET | 6000 | 0.6406 |
| 12:48 ET | 700 | 0.6406 |
| 12:56 ET | 3000 | 0.6449 |
| 01:01 ET | 1998 | 0.6408 |
| 01:19 ET | 190 | 0.642801 |
| 01:28 ET | 1910 | 0.64 |
| 01:32 ET | 4275 | 0.64 |
| 01:33 ET | 2388 | 0.6328 |
Sep 17, 2024
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection, from 1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
1:01PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ BioLine RX Initiated at Buy by Jones Trading, from 12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:15PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
BioLine RX Ltd | 53.0M | -0.8x | --- |
Kronos Bio Inc | 56.1M | -0.6x | --- |
LAVA Therapeutics NV | 43.1M | -1.8x | --- |
Singular Genomics Systems Inc | 39.3M | -0.4x | --- |
Kezar Life Sciences Inc | 40.1M | -0.4x | --- |
Omega Therapeutics Inc | 69.5M | -0.9x | --- |
Company Information
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Contact Information
- Headquarters
- Modi'in Technology Park 2 HaMa'ayan StreetMODIIN, Israel 7177871
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Aharon Schwartz
- Chief Executive Officer
- Philip Serlin
- Chief Financial Officer
- Mali Zeevi
- Vice President - Development
- Ella Sorani
- Vice President-Clinical & Medical Affairs
- Abi Vainstein-Haras
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $53.0M |
|---|---|
Revenue (TTM) | $11.7M |
Shares Outstanding | 80.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-0.76 |
Book Value | $0.18 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 4.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -391.76% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
